Skip to content

Comparison of Budesonide and saline on weaning from Mechanical ventilation

Comparison between Budesonide and saline use on the time of the weaning from Mechanical ventilation for patients in ICU

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT2016030920592N5
Enrollment
120
Registered
2016-05-08
Start date
2014-01-28
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

weaning of mechanical ventilation.

Interventions

Intervention 1: intervention:Budesonide This group received inhaler Budesonide 1 h before extubation and treatment continued up to 48 h after extubation. Patients underwent the therapy with bude
Treatment - Drugs
intervention:Budesonide This group received inhaler Budesonide 1 h before extubation and treatment continued up to 48 h after extubation. Patients underwent the therapy with budesonide at a dos
control: Normal Saline Normal Saline was administered intra venous at a dosage of 0.15 mg/kg, one hour before extubation. After extubation, the administration of normal saline continued at t

Sponsors

Vice chancellor for research, Shahid Beheshti University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
15 Years to 80 Years

Inclusion criteria

Inclusion criteria: The inclusion criteria: intubated patients difficult to wean; duration of ICU stay less than 21 days. The exclusion criteria: patients with bronchiectasis, sepsis or Systemic Inflammatory Response Syndrome, pleural effusion, and Ventilator-Associated Pneumonia

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Number of days of mechanical ventilation. Timepoint: In start of the study and after 5 days. Method of measurement: observation.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSeyed Mohammadreza hashemian

Masih Daneshvari Hospital

iran.criticalcare@yahoo.com+98 21 2610 9512

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026